- Raw materials
- Antibacterials
- Deoxyspergualin
Deoxyspergualin API Manufacturers & Suppliers
0 verified results
All Deoxyspergualin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Deoxyspergualin | CAS No: 89149-10-0 | GMP-certified suppliers
A medication that serves as an investigational immunosuppressive agent with potential applications in autoimmune diseases, organ transplant rejection, and cancer therapy.
Therapeutic categories
Product Snapshot
- Deoxyspergualin is an immunosuppressive agent formulated as an injectable small molecule
- It is primarily used for preventing organ transplant rejection and treating autoimmune conditions
- The compound remains investigational and has not yet received FDA or EMA approval
Clinical Overview
Although a specific approved clinical indication has not been established, deoxyspergualin’s therapeutic interest lies largely within immunologic and antineoplastic domains, as reflected in its drug categorization. It exhibits properties consistent with immunosuppressive agents and has been studied for possible protective roles including radiation protection.
The precise pharmacodynamics and mechanism of action for deoxyspergualin remain incompletely characterized in the public literature. Its effects are presumed to involve modulation of immune response pathways, contributing to its investigational applications in autoimmunity and transplant medicine. Key absorption, distribution, metabolism, and excretion (ADME) parameters have not been definitively reported; thus, further pharmacokinetic profiling is necessary to elucidate its disposition and optimize dosing strategies.
Safety and toxicity data are limited, emphasizing the investigational status of deoxyspergualin. Careful monitoring in clinical trials has been required to assess tolerability and adverse effect profiles. No marketed pharmaceutical products containing deoxyspergualin are currently available, reinforcing its role primarily as a research compound.
For formulation scientists and API sourcing professionals, procurement of deoxyspergualin should prioritize manufacturers adhering to stringent quality controls and regulatory compliance given its investigational status. Suppliers must provide comprehensive documentation including batch-to-batch consistency, purity specifications, and certification of analysis to support research integrity and regulatory submissions.
Identification & chemistry
| Generic name | Deoxyspergualin |
|---|---|
| Molecule type | Small molecule |
| CAS | 89149-10-0 |
| UNII | 57F9XM233R |
| DrugBank ID | DB12991 |
Formulation & handling
- Deoxyspergualin is a small molecule with low lipophilicity and limited water solubility, potentially requiring solubilizing agents for formulation.
- Given its physicochemical profile, the compound is more suited for parenteral administration rather than oral dosing due to solubility constraints.
- Formulation should consider stability under aqueous conditions given its investigational status and structural class.
Regulatory status
Deoxyspergualin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
